Gedea Biotech granted US patent

Gedea Biotech granted US patent

- for its antibiotic-free treatment pHyph for women with vaginal fungal infections

Swedish women’s health company Gedea Biotech today announced that it has been granted a patent (US 10,993,907) by the United States Patent and Trademark Office (USPTO) for thetreatment of fungal infections by the company’s compound glucono-δ-lactone (GDL). The patent can be kept in force until 2037. 

Gedea Biotech AB